Aerovate Therapeutics, Inc. financial data

Symbol
AVTE on Nasdaq
Industry
Pharmaceutical Preparations
Location
930 Winter Street, Suite M 500, Waltham, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 846 % -54.1%
Debt-to-equity 13.4 % +116%
Return On Equity -70.2 % -63%
Return On Assets -61.9 % -52.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 27.9 M shares +12.3%
Common Stock, Shares, Outstanding 27.9 M shares +12.4%
Entity Public Float 232 M USD +47.5%
Common Stock, Value, Issued 3 K USD +50%
Weighted Average Number of Shares Outstanding, Basic 27.8 M shares +12.2%
Weighted Average Number of Shares Outstanding, Diluted 27.8 M shares +12.2%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 70.8 M USD +57.9%
General and Administrative Expense 17.6 M USD +17.2%
Operating Income (Loss) -88.4 M USD -47.7%
Nonoperating Income (Expense) 1.81 M USD +220%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -75.5 M USD -46.6%
Income Tax Expense (Benefit) 56 K USD +124%
Net Income (Loss) Attributable to Parent -82.2 M USD -43.9%
Earnings Per Share, Basic -3.03 USD/shares -30.6%
Earnings Per Share, Diluted -3.03 USD/shares -30.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 9.12 M USD -65.7%
Cash, Cash Equivalents, and Short-term Investments 99.3 M USD -16.5%
Assets, Current 103 M USD -14.4%
Property, Plant and Equipment, Net 260 K USD -2.62%
Operating Lease, Right-of-Use Asset 725 K USD -20.2%
Other Assets, Noncurrent 2.6 M USD -1.96%
Assets 107 M USD -14.1%
Accounts Payable, Current 3.31 M USD -29.9%
Employee-related Liabilities, Current 1.33 M USD +30.9%
Liabilities, Current 15.5 M USD +45.9%
Operating Lease, Liability, Noncurrent 329 K USD -44.3%
Liabilities 15.9 M USD +40.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax -33 K USD +83.6%
Retained Earnings (Accumulated Deficit) -187 M USD -78.7%
Stockholders' Equity Attributable to Parent 90.9 M USD -19.6%
Liabilities and Equity 107 M USD -14.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -23.7 M USD -107%
Net Cash Provided by (Used in) Financing Activities 471 K USD +111%
Net Cash Provided by (Used in) Investing Activities 8.83 M USD -42.6%
Common Stock, Shares Authorized 150 M shares 0%
Common Stock, Shares, Issued 27.9 M shares +12.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -14.4 M USD -444%
Deferred Tax Assets, Valuation Allowance 43.6 M USD +87.2%
Deferred Tax Assets, Gross 43.8 M USD +85.7%
Operating Lease, Liability 774 K USD -19.7%
Depreciation 28 K USD +33.3%
Payments to Acquire Property, Plant, and Equipment 142 K USD -27.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -82 M USD -44.7%
Lessee, Operating Lease, Liability, to be Paid 813 K USD -21.4%
Operating Lease, Liability, Current 445 K USD +19.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 242 K USD -52.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 571 K USD +101%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 39 K USD -44.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 242 K USD -50.5%
Deferred Tax Assets, Operating Loss Carryforwards 16.2 M USD +37.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10 M shares 0%
Unrecognized Tax Benefits 2.21 M USD +123%
Lessee, Operating Lease, Liability, to be Paid, Year Four 242 K USD
Operating Lease, Payments 127 K USD +3.25%
Additional Paid in Capital 278 M USD +27.5%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 206 K USD -31.8%
Share-based Payment Arrangement, Expense 13.7 M USD +101%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%